Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is among the best low-priced growth stocks to buy now. Analysts at H.C. Wainwright have reaffirmed their ‘Buy’ rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), while reducing the price target to $55 from$70, implying a potential upside of nearly 100%. The 21.43% downside in guidance follows the company’s Phase 3 trial failure. On Wednesday, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced that its key Phase 3 RECONNECT trial for ZYN002 ...